Company news
Agenus Inc. news in 2024
Agenus Inc.'s news releases, calls and decks from 2024, newest first.
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
December 17, 2024
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
December 4, 2024
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
November 26, 2024
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
November 11, 2024
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
November 6, 2024
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
November 4, 2024
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
September 12, 2024
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
September 8, 2024
Agenus to Participate in September Investor Conferences
September 2, 2024
Agenus Reports Second Quarter 2024 Operational and Financial Results
August 7, 2024
Agenus Announces Appointment of Tom Harrison to Board of Directors
August 7, 2024
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
August 6, 2024
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
July 25, 2024
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
July 17, 2024
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
June 27, 2024
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
June 26, 2024
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
June 16, 2024
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
June 12, 2024
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 23, 2024
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
May 22, 2024
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
May 15, 2024
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
May 6, 2024
Agenus Reports First Quarter 2024 Results
May 6, 2024
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 30, 2024
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
April 23, 2024
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
April 22, 2024
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
April 11, 2024
Agenus Announces Reverse Stock Split of Common Stock
April 4, 2024
Agenus Reports Fourth Quarter and Full Year 2023 Results
March 13, 2024
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
March 5, 2024
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
February 28, 2024
Agenus to Participate in Leerink Partners Global Biopharma Conference
February 25, 2024
Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design
February 14, 2024
Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
January 30, 2024
Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population
January 21, 2024
Agenus to Participate in B. Riley Healthcare Conference
January 3, 2024